Navigation Links
Novavax Opens Its First U.S. Vaccine Plant

Company, State and County Representatives Unveil State-of-the-Art Facility

in Rockville, MD

ROCKVILLE, Md., May 1 /PRNewswire-FirstCall/ -- Officials from Novavax, Inc. (Nasdaq: NVAX), the State of Maryland and Montgomery County today celebrated the opening of Novavax's new state-of-the-art vaccine production facility at the company's headquarters in Rockville, Maryland. The 5,000 square-foot, $5 million pilot and commercial-scale manufacturing plant will be used to produce vaccines addressing a broad range of infectious diseases. The facility will initially supply influenza vaccine for the company's current clinical programs with planned annual capacity of 10 million doses.

"The completion of this facility represents a major milestone for Novavax and a significant accomplishment for our development team," said Novavax president and chief executive officer Rahul Singhvi, Sc.D. "This facility is seen as a model vaccine plant for production of all of our virus-like-particle-based vaccines and will serve as a prototype for other similar local country facilities through collaborators such as GE Healthcare. It incorporates new processes that are designed to increase production yields with significantly less infrastructure and capital cost compared to current approved vaccine facilities. Our production technology, which can be used to produce many types of vaccines in a single facility, combined with our use of disposable materials, offer the potential advantage of simple portability of production equipment to sites around the world, where vaccines may be urgently needed."

Unlike traditional egg-based vaccine production, which is expensive and can require large centralized manufacturing plants with complex infrastructure, the Novavax facility employs unique cell-based technology and disposable manufacturing systems which require less production infrastructure and represent a simpler and potentially more efficient approach to vaccine production. The novel methods being applied at Novavax's new facility will enable the company to produce vaccines within twelve weeks of flu strain identification, which is less than half the time required by current manufacturers of approved vaccines. These methods should also enable the company to respond faster to seasonal or pandemic flu outbreaks once the vaccines in development are approved.

Novavax has four proprietary vaccine candidates in development addressing pandemic influenza, seasonal flu, varicella zoster and an undisclosed infectious disease target. The company's lead vaccine candidate to protect against pandemic influenza is currently in Phase II clinical testing.

"I congratulate Novavax on the opening of this impressive facility and wish them continued success in developing innovative, vital vaccines to prevent infectious diseases such as influenza," said Montgomery County Executive Isiah Leggett. "We are very pleased to have Novavax headquartered in Montgomery County, as they are certainly one of our brightest, most promising biotechnology companies and we look forward to their continued growth and success."

"Novavax's decision to relocate their corporate headquarters to Maryland and expand with this new state-of-the-art vaccine production facility is a tremendous win for both Montgomery County and the State of Maryland," said David W. Edgerley, Secretary of the Maryland Department of Business and Economic Development. "This new facility will not only build on Governor O'Malley's vision to strengthen our State's reputation as a bioscience powerhouse, but also puts Maryland on the forefront of disease control and prevention."

About Novavax

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, highly potent, recombinant vaccines utilizing a new, efficient manufacturing solution.

Forward-Looking Statements

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues, operating expenses, and clinical developments are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the failure by Novavax to secure and maintain relationships with collaborators; risks relating to the early stage of Novavax's product candidates under development; uncertainties relating to clinical trials; results of further animal and human testing may result in data inconsistent with previously announced data or with our expectations; risks relating to the commercialization, if any, of Novavax's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility, and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.

SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Novavax CEO to Present at the World Vaccine Congress 2008
2. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
3. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
4. Novavax CEO to Present at BIO CEO & Investor Conference
5. Cytochroma opens U.S. headquarters in Illinois
6. Hologic, Inc. to Release Second Quarter Fiscal 2008 Operating Results Thursday, May 1st Before Market Opens
7. Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center
8. Transgenomic Opens Pharmacogenomics Laboratory in China
9. Finesse Solutions Opens New E-Store for Sensors
10. GRAS Status Opens Door to U.S. Food Industry
11. Antibody Engineering Company f-Star Opens Second Research Site in Cambridge, UK
Post Your Comments:
(Date:10/12/2015)... , October 12, 2015 cell surface ... billion by 2022, according to a new report by Grand ... to rise in incidence of oncology diseases and other cell-associated ... is expected to reach USD 6.49 billion by 2022, according ... growth in demand can be attributed to rise in incidence ...
(Date:10/12/2015)... CAESAREA, Israel , October 12, 2015 ... of the Dario™ Diabetes Management Solution, today announced its ... a patient case study at MobiHealth,s 5th EAI ... Focused on, "Transforming healthcare through innovations in mobile and ... London, England from October 14 - ...
(Date:10/12/2015)... ... October 12, 2015 , ... NeuMedics Inc., is a specialty ... diseases that can safely and chronically be administered as an eye drop, announced today ... by The Cleveland Clinic and taking place October 25th to October 28th at The ...
(Date:10/10/2015)... Maryland , 10. Oktober, 2015 ... Matsui (Abgeordnete der Demokratischen Partei für Kalifornien) ihre ... bis 17. Oktober) in die Aufzeichnungen des Kongresses ... Plasma Protein Therapeutics Association (PPTA) und ihren ... , Hebung des Bewusstseins über Plasmaspenden weltweit ...
Breaking Biology Technology:
(Date:9/24/2015)... , September 24, 2015 ... september 2015 Kerv ( ... finanstjänster, lanserar idag världens första kontaktlösa betalningsring ... in 77 000 GBP för massproduktion via ... ) , Kerv-bärare kan ...
(Date:9/10/2015)... -- Pursuant Health has collaborated with health experts ... image-based health risk assessment (HRA) optimized for Pursuant ... assessment quantifies user results into an easily understood ... biological age based on personal health habits, characteristics ... Comprised of age, gender, and risk ...
(Date:9/8/2015)... Sept. 8, 2015  Affectiva, global leader in ... a Service, a new data solution, and version ... on Affectiva,s highly accurate and patented science, these ... slated to transform industries such as market research, ... customer experience, online education, HR, automotive, robotics, healthcare ...
Breaking Biology News(10 mins):